Table 1. Clinical characteristics.

Items	Clinical characteristics
Age (years), mean ± SD	58±13
Sex (n)	Male (n=16), female (n=44)
Disease duration (months), median (range)	81 (10–564)
Disease subsets (n)	lSSc (n=33), dSSc (n=27)
Extent of skin fibrosis assessed by the modified Rodnan Skin score, median (range)/51	9.5 (0–31)/51
Antibody profile (n)	ANA positive (n=59) ACA positive (n=16) Scl-70 positive (n=23) RNA-polymerase III positive (n=7)
Major organ involvement except lung fibrosis ± (n)	Heart (n=18) Gastrointestinal tract (n=10) Pulmonary arterial hypertension (n=5)
Lung function parameters, mean ± SD (range)
FVC (%) predicted	92.49±22.1 (41–136)
FEV1 (%) predicted	89.76±19.74 (42–122.2)
TLC (%) predicted	90.74±2.83 (31.1–139)
DCLO (%) predicted	76.32±19.3 (40–123)